Floatz logo

Urokinase-Derived Peptide A6

Fallopian Tube Carcinoma

Gynecologic Oncology Groupprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
University of Washington
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
The Netherlands Cancer Institute
Phase 3BB
Inno-206
Advenchen Laboratories, LLC
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Urokinase-Derived Peptide A6 is also rated in:

ovarian clear cell cystadenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian endometrioid adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian Brenner tumorDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →